Boston Scientific (BSX)

Investors weigh softer WATCHMAN and urology demand against a still-active device pipeline and capital deployment moves, today, May 27, 2026.

The medical device giant just opened its wallet for a stake in a privately held company with a groundbreaking product.

This biotech focuses on biologic therapies for immunological diseases, with lead candidates in nephrology and infectious disease.

Biotech firm Nektar Therapeutics advances a pipeline of immunology and oncology candidates through research-driven collaborations.

GeneDx Holdings delivers AI-powered clinical and genomic data analysis for healthcare providers seeking precision medicine solutions.

Large-cap stocks usually command their industries because they have the scale to drive market trends. The flip side though is that their sheer size can limit...

Growth is a hallmark of all great companies, but the laws of gravity eventually take hold. Those who rode the COVID boom and ensuing tech selloff in 2022 wil...

Don't let their current weakness deter you. Sometimes, investors collectively misread and misprice the situation.

Boston Scientific’s first quarter saw a strong positive market reaction, underpinned by solid organic sales growth and improved operating margins. Management...

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. But speed bumps such as inventory de...

Medical device company Boston Scientific (NYSE:BSX) announced better-than-expected revenue in Q1 CY2026, with sales up 11.6% year on year to $5.20 billion. O...